LOXL2 and idiopathic pulmonary fibrosis: In the present study, we confirmed that LOXL2 was increased in IPF compared with normal lung samples and cells, but the reduction in collagen cross-linking with Simtuzumab clearly enhanced the synthetic and functional activity of both normal and IPF fibroblasts in the assays we explored.